NO965012D0 - Farmasöytisk preparat som omfatter glukagon - Google Patents

Farmasöytisk preparat som omfatter glukagon

Info

Publication number
NO965012D0
NO965012D0 NO965012A NO965012A NO965012D0 NO 965012 D0 NO965012 D0 NO 965012D0 NO 965012 A NO965012 A NO 965012A NO 965012 A NO965012 A NO 965012A NO 965012 D0 NO965012 D0 NO 965012D0
Authority
NO
Norway
Prior art keywords
glucagon
pharmaceutical composition
preparation
dipeptide
excipient
Prior art date
Application number
NO965012A
Other languages
English (en)
Other versions
NO965012L (no
Inventor
Troels Kornfelt
Henrik Rasmussen
Flemming Steen Jensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO965012L publication Critical patent/NO965012L/no
Publication of NO965012D0 publication Critical patent/NO965012D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO965012A 1994-05-26 1996-11-25 Farmasöytisk preparat som omfatter glukagon NO965012D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK59094 1994-05-26
PCT/DK1995/000208 WO1995032730A1 (en) 1994-05-26 1995-05-26 A pharmaceutical preparation comprising glucagon

Publications (2)

Publication Number Publication Date
NO965012L NO965012L (no) 1996-11-25
NO965012D0 true NO965012D0 (no) 1996-11-25

Family

ID=8095292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965012A NO965012D0 (no) 1994-05-26 1996-11-25 Farmasöytisk preparat som omfatter glukagon

Country Status (12)

Country Link
US (1) US5652216A (no)
EP (1) EP0760677B1 (no)
JP (1) JP3295430B2 (no)
AT (1) ATE205090T1 (no)
AU (1) AU694229B2 (no)
CA (1) CA2191317A1 (no)
DE (1) DE69522562T2 (no)
DK (1) DK0760677T3 (no)
ES (1) ES2163511T3 (no)
FI (1) FI964682A (no)
NO (1) NO965012D0 (no)
WO (1) WO1995032730A1 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (en) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP4072319B2 (ja) * 1998-03-13 2008-04-09 ノヴォ ノルディスク アクティーゼルスカブ 安定化水溶性ペプチド溶液
DE69918070T2 (de) * 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
JP2002193830A (ja) * 1998-10-19 2002-07-10 High Chem Co Ltd 経鼻投与用医薬製剤
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
ES2298378T3 (es) * 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
WO2005049061A2 (en) * 2003-11-20 2005-06-02 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2009048462A1 (en) 2007-10-09 2009-04-16 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
EP1752146A4 (en) * 2004-05-19 2007-10-10 Ajinomoto Kk THERAPEUTIC AGENT AGAINST DIABETES
ES2442223T3 (es) * 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
BRPI0517341A (pt) * 2004-11-12 2008-10-07 Novo Nordisk As composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009055736A1 (en) 2007-10-25 2009-04-30 Dexcom, Inc. Systems and methods for processing sensor data
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
US8682440B2 (en) 2009-08-03 2014-03-25 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
WO2011049713A2 (en) 2009-10-22 2011-04-28 Biodel Inc. Stabilized glucagon solutions
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN103442695B (zh) 2011-03-10 2016-05-04 Xeris药物公司 肠胃外注射用肽药物的稳定制剂
AU2012332556B2 (en) 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
US9782344B2 (en) * 2013-08-22 2017-10-10 Zp Opco, Inc. Stable glucagon peptide formulations
EP3035952B1 (en) * 2013-08-22 2018-12-26 ZP Opco, Inc. Stable glucagon peptide formulations
EP3871709A1 (en) 2014-08-06 2021-09-01 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
AU2016287843B2 (en) * 2015-07-02 2021-06-17 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
DK3630061T3 (da) 2017-06-02 2024-06-24 Xeris Pharmaceuticals Inc Udfældningsresistente, småmolekylære lægemiddelformuleringer
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
ES2044941T5 (es) * 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat

Also Published As

Publication number Publication date
CA2191317A1 (en) 1995-12-07
EP0760677B1 (en) 2001-09-05
ES2163511T3 (es) 2002-02-01
WO1995032730A1 (en) 1995-12-07
EP0760677A1 (en) 1997-03-12
ATE205090T1 (de) 2001-09-15
AU2560695A (en) 1995-12-21
DE69522562T2 (de) 2002-07-11
US5652216A (en) 1997-07-29
FI964682A (fi) 1997-01-20
AU694229B2 (en) 1998-07-16
FI964682A0 (fi) 1996-11-25
NO965012L (no) 1996-11-25
JPH10500696A (ja) 1998-01-20
DK0760677T3 (da) 2001-12-31
JP3295430B2 (ja) 2002-06-24
DE69522562D1 (de) 2001-10-11

Similar Documents

Publication Publication Date Title
NO965012D0 (no) Farmasöytisk preparat som omfatter glukagon
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
SE8804629D0 (sv) New therapeutically active compounds
NO964700D0 (no) Nye aminosyrederivater, fremgangsmåte til deres fremstilling og farmasöytiske blandinger som inneholder disse forbindelser
HUP9701059A2 (hu) Stronciumsók alkalmazása ízületi bántalmak kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
HUP9903336A3 (en) Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds and pharmaceutical compositions containing the same
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
BR9709845B1 (pt) preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
SE8804628D0 (sv) New compounds
DK1014948T3 (da) Lyofiliseret farmaceutisk præparat som er beregnet til at efterligne et lægemiddel på basis af proteiner eller polypeptider
PT862575E (pt) Novos derivados de geranilgeranilo processo para a sua preparacao e composicoes farmaceuticas relacionadas
DK370586A (da) N-(4-piperidyl)benzamid-forbindelser, 1-substituerede 4-aminopiperidiner til anvendelse som udgangsmateriale ved deres fremstilling og farmaceutiske praeparater
NO912414D0 (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
EE03803B1 (et) a-amino- ja tsüklopentaan-ß-aminohapet(-happeid) ja/või nende derivaate sisaldavad segud ja dipeptiidid, dipeptiidide valmistamismeetod ning nimetatud segusid ja/või dipeptiide sisaldavad ravimid
CO4910113A1 (es) Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion
DE60302951D1 (de) Pyroglutaminsäure-salz von Amlodipin
HUP9701293A2 (hu) Új, kellemetlen íztől mentes sók és ezeket tartalmazó gyógyszerkészítmények
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
DK0946585T3 (da) Steroidforbindelser substitueret i stilling 11, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application